Literature DB >> 16798034

Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies.

Néstor A Molfino1, Peter K Jeffery.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a major worldwide health burden with increasing morbidity, mortality and health care cost. It is a slowly progressive chronic inflammatory condition that affects the conducting airways (both large and small) and lung parenchyma. In COPD, inflammation is evident early on even in mild disease and increases with disease severity. Recent advances in our knowledge demonstrate, by comparison with asthma, the distinctive, "abnormal" or exaggerated inflammatory processes involved in the pathogenesis of COPD and thus identify novel therapeutic targets that could potentially impact on disease progression. The present review will focus on what is known of the abnormal inflammatory response of COPD in different regions of the conducting airways and lung. Novel, potentially promising approaches to therapy are presented.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16798034     DOI: 10.1016/j.pupt.2006.04.003

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  9 in total

1.  Edible Myrciaria vexator fruits: bioactive phenolics for potential COPD therapy.

Authors:  Keyvan Dastmalchi; Gema Flores; Shi-Biao Wu; Chunhui Ma; Abdoulaye J Dabo; Kathleen Whalen; Kurt A Reynertson; Robert F Foronjy; Jeanine M D Armiento; Edward J Kennelly
Journal:  Bioorg Med Chem       Date:  2012-05-14       Impact factor: 3.641

2.  A study on chronic obstructive pulmonary disease diagnosis using multilayer neural networks.

Authors:  Orhan Er; Feyzullah Temurtas
Journal:  J Med Syst       Date:  2008-10       Impact factor: 4.460

3.  Use of glucosamine and chondroitin in relation to mortality.

Authors:  Griffith A Bell; Elizabeth D Kantor; Johanna W Lampe; Danny D Shen; Emily White
Journal:  Eur J Epidemiol       Date:  2012-07-25       Impact factor: 8.082

4.  The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts.

Authors:  F Lamyel; M Warnken-Uhlich; W K Seemann; K Mohr; E Kostenis; A S Ahmedat; M Smit; R Gosens; H Meurs; A Miller-Larsson; Kurt Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-21       Impact factor: 3.000

5.  A comparative study on chronic obstructive pulmonary and pneumonia diseases diagnosis using neural networks and artificial immune system.

Authors:  Orhan Er; Cengiz Sertkaya; Feyzullah Temurtas; A Cetin Tanrikulu
Journal:  J Med Syst       Date:  2009-12       Impact factor: 4.460

6.  Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients.

Authors:  Richard A Urbanowicz; Jonathan R Lamb; Ian Todd; Jonathan M Corne; Lucy C Fairclough
Journal:  Respir Res       Date:  2010-06-11

Review 7.  Pulmonary fibroblasts, an emerging target for anti-obstructive drugs.

Authors:  Kurt Racké; Susanne Haag; Amit Bahulayan; Mareille Warnken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-13       Impact factor: 3.000

8.  Targeting lung inflammation: novel therapies for the treatment of COPD.

Authors:  Hongwei Yao; Willem I de Boer; Irfan Rahman
Journal:  Curr Respir Med Rev       Date:  2008

9.  Role of Epac1 in mediating anti-proliferative effects of prostanoid EP(2) receptors and cAMP in human lung fibroblasts.

Authors:  S Haag; M Warnken; U R Juergens; K Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-22       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.